Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Moexipril. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE known ✓ | P12821 | 15/20 | 0.98 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.98 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.79 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Moexipril SCHEMBL3967866 | 1.00 | ACE (0.98) | ACEPDE3AABCB11LMNASMN1; SMN2 | |
| Moexipril SCHEMBL28096307 | 1.00 | ACE (0.98) | ACEPDE3AABCB11LMNASMN1; SMN2 | |
| Moexipril SCHEMBL30903896 | 1.00 | ACE (0.98) | ACEPDE3AABCB11LMNASMN1; SMN2 | |
| Moexipril SCHEMBL9809013 | 1.00 | ACE (0.98) | ACEPDE3AABCB11LMNASMN1; SMN2 | |
| Moexipril SCHEMBL29383460 | 1.00 | ACE (0.98) | ACEPDE3AABCB11LMNASMN1; SMN2 | |
| Moexipril SCHEMBL14660386 | 1.00 | ACE (0.98) | ACEPDE3AABCB11LMNASMN1; SMN2 | |
| Moexipril SCHEMBL5386742 | 1.00 | ACE (0.98) | ACEPDE3AABCB11LMNASMN1; SMN2 | |
| Moexipril SCHEMBL11268790 | 0.99 | ACE (0.97) | ACEPDE3AABCB11LMNASMN1; SMN2 | |
| Moexipril SCHEMBL683321 | 0.99 | ACE (1.00) | ACEPDE3AABCB11LMNASMN1; SMN2 | |
| Moexipril SCHEMBL22175779 | 0.99 | ACE (1.00) | ACEPDE3AABCB11LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3984 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4691556-A2 | HUMANIZED ANTI-ACTH ANTIBODIES AND USE THEREOF | H. Lundbeck A/S (DK) | 2026-02-11 | — | — | EP | claimed |
| US-20230174641-A1 | ANTI-ACTH ANTIBODIES AND USE THEREOF | H LUNDBECK AS (DK) | 2023-06-08 | — | — | US | claimed |
| US-20230134521-A1 | COMPOUNDS FOR METHODS FOR PROMOTING FEMALE REPRODUCTIVE HEALTH THROUGH MEDIATION OF RENIN ANGIOTENSIN FUNCTION | SHANAHAN MICHAEL EMIL (US) | 2023-05-04 | — | — | US | claimed |
| US-20210198741-A1 | IDENTIFICATION OF SPATIAL BIOMARKERS OF HEART DISORDERS AND METHODS OF USING THE SAME | 10X GENOMICS, INC. | 2021-07-01 | — | — | US | claimed |
| EP-3835319-A1 | HUMANIZED ANTI-ACTH ANTIBODIES AND USE THEREOF | Alder Biopharmaceuticals, Inc. (US) | 2021-06-16 | — | — | EP | claimed |
| EP-3753950-A2 | ANTI-PCSK9 ANTIBODIES AND USE THEREOF | H. Lundbeck A/S (DK) | 2020-12-23 | — | — | EP | claimed |
| US-20200317772-A1 | ANTI-ACTH ANTIBODIES AND USE THEREOF | ALDERBIO HOLDINGS LLC (US) | 2020-10-08 | — | — | US | claimed |
| US-20190085073-A1 | HUMANIZED ANTI-ACTH ANTIBODIES AND USE THEREOF | H. LUNDBECK A/S (DK) | 2019-03-21 | — | — | US | claimed |
| US-10154856-B2 | Therapeutic substance transfer catheter and method | SILLENDER MARK (AU) | 2018-12-18 | — | — | US | claimed |
| US-10149909-B2 | Fortifier | TORAY INDUSTRIES, INC. (JP) | 2018-12-11 | — | — | US | claimed |
| JP-2003508349-A | — | — | 2003-03-04 | — | — | JP | claimed |
| WO-2002058731-A2 | COMBINATIONS OF STEROL ABSORPTION INHIBITOR(S) WITH CARDIOVASCULAR AGENT(S) FOR THE TREATMENT OF VASCULAR CONDITIONS | SCHERING CORPORATION (US) | 2002-08-01 | — | — | WO | claimed |
| US-20020049155-A1 | Cobalamin compounds useful as cardiovascular agents and as imaging agents | HOGENKAMP HENRICUS P C (US) | 2002-04-25 | — | — | US | claimed |
| US-20020037858-A1 | Pharmaceutical compositions comprising moexipril magnesium | APOTEX, INC. (CA) | 2002-03-28 | — | — | US | claimed |
| EP-1183011-A1 | METHOD OF TREATING ANGINA AND/OR ANGINAL EQUIVALENTS, AND PHARMACEUTICAL COMPOSITIONS AND KIT RELATED THERETO | Esperion Mergerco, Inc. (US) | 2002-03-06 | — | — | EP | claimed |
| WO-2001092283-A2 | COBALAMIN COMPOUNDS USEFUL AS CARDIOVASCULAR AGENTS AND AS IMAGING AGENTS | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2001-12-06 | — | — | WO | claimed |
| EP-1142878-A2 | Pharmaceutical compositions comprising moexipril magnesium | SHERMAN, Bernard Charles (CA) | 2001-10-10 | — | — | EP | claimed |
| WO-2000069412-A1 | METHOD OF TREATING ANGINA AND/OR ANGINAL EQUIVALENTS, AND PHARMACEUTICAL COMPOSITIONS AND KIT RELATED THERETO | ESPERION LUV DEVELOPMENT, INC. (US) | 2000-11-23 | — | — | WO | claimed |
| EP-0220107-A2 | Use of angiotensin-converting enzyme inhibitors in macular degeneration | MERCK & CO. INC. (US) | 1987-04-29 | — | — | EP | claimed |
| US-4656188-A | Ace inhibitors in macular degeneration | MERCK & CO., INC. (US) | 1987-04-07 | — | — | US | claimed |